Metabotropic Glutamate Receptors as Therapeutic Targets for Cognitive Disorders

Author(s): A. Gravius, M. Pietraszek, A. Dekundy, W. Danysz

Journal Name: Current Topics in Medicinal Chemistry

Volume 10 , Issue 2 , 2010

Become EABM
Become Reviewer
Call for Editor


Since more than one decade, metabotropic glutamate receptors have been under investigation as targets for various CNS disorders such as anxiety, pain, depression, schizophrenia, Alzheimers disease and Parkinsons disease. It has been shown that some mGluRs play a crucial role in cognitive processes such as learning and memory, which was initially, demonstrated using knockout mice for each receptor subtype. Later, selective pharmacological tools were developed allowing more specific examinations of the involvement of mGluR1-8 in various forms of learning and memory. Ligands for group I and II mGluRs have been proposed as promising candidates for the treatment of cognitive disorders such as schizophrenia, Fragile X syndrome, Alzheimers and Parkinsons disease and posttraumatic stress disorder, of which some have made it to clinical testing. The present paper reviews relevant data on the role of mGluRs in learning and cognition processes focusing on their utility as targets for cognition enhancement in several CNS diseases.

Keywords: mGluR, learning, metabotropic glutamate receptors, cognition

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Published on: 01 March, 2012
Page: [187 - 206]
Pages: 20
DOI: 10.2174/156802610790411018
Price: $65

Article Metrics

PDF: 15